SOURCE: World Street Fundamentals

June 28, 2011 09:00 ET

Equity Research on Pain Therapeutics, Inc. and Durect Corporation - No Pain, No Gain

HONG KONG--(Marketwire - Jun 28, 2011) - Today, www.WorldStreetFundamentals.com released its industry report highlighting Pain Therapeutics, Inc. (NASDAQ: PTIE) and Durect Corporation (NASDAQ: DRRX). Full fundamental and technical analysis is available at www.WorldStreetFundamentals.com/Reports.php.

This sector demonstrates renewed investor interest as new and lucrative therapies come to market. The FDA approved the first new drug in 50 years to treat auto-immune disorder lupus in March 2011, and we expect approval of new treatments for Hepatitis C virus around mid-year. The 2010 health care reform act authorized the FDA, will establish a regulatory pathway for approving "biosimilar" drugs, which in turn will increase production and shorten FDA approval times. Pharmaceuticals should remain one of the widest-margin industries, with prospects enhanced by demographic growth in the elderly and new drugs stemming from discoveries in genomics and biotechnology.

World Street Fundamentals has highlighted Pain Therapeutics, Inc. as a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. The Company and King jointly managed a Phase III clinical program and New Drug Application (NDA) submission for REMOXY. It is also developing a pipeline of drug candidates in the area of oncology and hematology. The entire report on Pain Therapeutics, Inc. (NASDAQ: PTIE) is available here:www.WorldStreetFundamentals.com/ViewFullReport.245.php.

World Street has highlighted Durect Corporation as a specialty pharmaceutical company focused on the development of pharmaceutical products based on the drug delivery technology platforms. The product pipeline consists of six investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), one program in Phase III, two programs in Phase II and two programs in Phase I. The entire report on Durect Corporation (NASDAQ: DRRX) is available here: www.WorldStreetFundamentals.com/ViewFullReport.138.php.

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets. Covering the top performers in the hottest sectors and providing clarity to investors around the world.

Contact Information